{"id":"https://openalex.org/W2305512101","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3517","title":"Phase I trial with a novel oral NF-\u03baB/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies","display_name":"Phase I trial with a novel oral NF-\u03baB/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W2305512101","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3517","mag":"2305512101"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.3517","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3517","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.3517","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"D. S. Hong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. S. Hong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Kurzrock","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089509810","display_name":"Jeffrey G. Supko","orcid":"https://orcid.org/0000-0002-4599-3267","observed_orcids":["https://orcid.org/0000-0002-4599-3267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. G. Supko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049839632","display_name":"Donald P. Lawrence","orcid":"https://orcid.org/0000-0001-5288-9110","observed_orcids":["https://orcid.org/0000-0001-5288-9110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. P. Lawrence","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113709286","display_name":"J. J. Wheler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Wheler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"C. J. Meyer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. J. Meyer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"J. W. Mier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. W. Mier","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110692113","display_name":"Micheal Andreeff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Andreeff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045419282","display_name":"Geoffrey Ira Shapiro","orcid":"https://orcid.org/0000-0002-3331-4095","observed_orcids":["https://orcid.org/0000-0002-3331-4095"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. I. Shapiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5109548084","display_name":"Bruce Jeffrey Dezube","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. J. Dezube","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"3517","last_page":"3517"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.8471999764442444,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.8471999764442444,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11332","display_name":"Genomics, phytochemicals, and oxidative stress","score":0.05050000175833702,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11503","display_name":"Cytokine Signaling Pathways and Interactions","score":0.015699999406933784,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bardoxolone-methyl","display_name":"bardoxolone methyl","score":0.9860000014305115},{"id":"https://openalex.org/keywords/nf-kappab-inhibition","display_name":"NF-\u03baB inhibition","score":0.8569999933242798},{"id":"https://openalex.org/keywords/stat3-inhibition","display_name":"STAT3 inhibition","score":0.9990000128746033},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7570000290870667},{"id":"https://openalex.org/keywords/lymphoid-malignancies","display_name":"lymphoid malignancies","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7929999828338623},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8930000066757202},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9829999804496765},{"id":"https://openalex.org/keywords/reactive-oxygen-species-signaling","display_name":"reactive oxygen species signaling","score":0.7450000047683716},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8270000219345093},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9629999995231628},{"id":"https://openalex.org/keywords/medullary-thyroid-carcinoma","display_name":"medullary thyroid carcinoma","score":0.8420000076293945},{"id":"https://openalex.org/keywords/anaplastic-thyroid-carcinoma","display_name":"anaplastic thyroid carcinoma","score":0.8140000104904175},{"id":"https://openalex.org/keywords/leukocytosis","display_name":"leukocytosis","score":0.8949999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8045167922973633},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4588210880756378},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.44319605827331543},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40857401490211487},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40165138244628906},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33922433853149414}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.3517","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3517","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.3517","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W796471661","https://openalex.org/W2267475740","https://openalex.org/W7098059942","https://openalex.org/W2028689349","https://openalex.org/W2750729412","https://openalex.org/W2087633043","https://openalex.org/W2087928294","https://openalex.org/W4379282666","https://openalex.org/W2021713593","https://openalex.org/W2487613987"],"abstract_inverted_index":{"3517":[0],"Background:":[1],"RTA":[2,57,74,95,154,290],"402":[3,58,75,96,155,291],"(CDDO-Me)":[4],"is":[5,112,292],"a":[6,182,326],"first-in-class":[7,286],"antioxidant":[8,287],"inflammation":[9,288],"modulator":[10,289],"with":[11,61,162,184,256,266,299,321],"potent":[12],"anticancer":[13],"and":[14,30,32,52,68,138,213,224,245,281,314,316,328],"anti-":[15],"inflammatory":[16],"activity.":[17],"The":[18,40,110,149,285],"drug":[19],"suppresses":[20],"ROS-mediated":[21],"signaling":[22],"through":[23],"suppression":[24],"of":[25,34,43,56,73,135,153,164,196,211,248,271,310],"pro-inflammatory":[26],"transcription":[27,36],"factors":[28],"NF-\u03baB":[29,212],"STAT3":[31],"induction":[33],"antioxidant/detoxification":[35],"factor":[37],"Nrf2.":[38],"Methods:":[39],"primary":[41],"objectives":[42],"the":[44,49,71,246],"study":[45],"were":[46],"to":[47,69,99,107,127,243,253,296,303],"determine":[48],"DLT,":[50],"MTD":[51,111,141],"phase":[53],"II":[54,336],"dose":[55,104,132],"in":[59,181,228,263,275,279,332],"patients":[60,101,137,172,191,265],"advanced":[62],"solid":[63],"tumors":[64],"or":[65,343,346],"lymphoid":[66],"malignancies;":[67],"characterize":[70],"pharmacokinetics":[72],"given":[76],"orally":[77],"once":[78],"daily":[79],"for":[80,174,199],"21":[81],"days":[82],"every":[83],"28":[84],"days.":[85],"Dose":[86],"escalation":[87],"proceeded":[88],"via":[89],"an":[90],"accelerated":[91],"titration":[92],"design.":[93],"Results:":[94],"was":[97,119,156,179,226,240,250,261,273],"administered":[98],"34":[100],"at":[102,116,140,231],"10":[103],"levels":[105],"(5":[106],"1,300":[108,117],"mg/day).":[109],"900":[113,297],"mg/day;":[114],"DLT":[115],"mg/day":[118,298],"asymptomatic":[120],"Grade":[121,129,147],"3":[122],"LFT":[123],"elevation,":[124],"which":[125,197],"resolved":[126],"\u2264":[128],"1":[130,207],"upon":[131],"reduction.":[133],"50%":[134],"all":[136],"40%":[139],"had":[142,192],"no":[143],"toxicities":[144],"greater":[145],"than":[146],"1.":[148],"median":[150],"biological":[151],"half-life":[152],"33.1":[157],"h":[158],"(range,":[159],"18\u201398":[160],"h),":[161],"volume":[163],"distribution":[165],"suggesting":[166],"extensive":[167],"tissue":[168],"uptake.":[169],"Of":[170],"18":[171],"evaluable":[173],"efficacy,":[175],"one":[176],"Partial":[177],"Response":[178],"observed":[180,227,262],"patient":[183],"anaplastic":[185],"thyroid":[186],"cancer.":[187],"A":[188],"further":[189],"9":[190],"stable":[193,268],"disease,":[194],"6":[195],"lasted":[198],"6\u201312":[200],"months":[201],"(3":[202],"melanoma,":[203],"2":[204],"renal":[205],"cell,":[206],"medullary":[208],"thyroid).":[209],"Suppression":[210],"STAT3,":[214,313],"as":[215,217,233,235],"well":[216,293],"downstream":[218],"targets":[219,311],"iNOS,":[220],"cyclin":[221],"D1,":[222],"COX-2,":[223],"arginase,":[225],"multiple":[229],"biopsies":[230],"doses":[232],"low":[234],"40":[236],"mg/day.":[237],"TUNEL":[238],"positivity":[239],"increased":[241,251],"up":[242,252,295,302],"6-fold,":[244],"presence":[247],"macrophages":[249],"10-fold.":[254],"Consistent":[255],"dual":[257],"NF-\u03baB/STAT3":[258],"suppression,":[259],"leukocytosis":[260],"several":[264,333],"prolonged":[267,300,329],"disease.":[269],"Induction":[270],"Nrf2":[272,315],"demonstrated":[274],"PBMCs":[276],"by":[277],"increases":[278],"NQO1":[280],"gamma-GCS":[282],"mRNA.":[283],"Conclusions:":[284],"tolerated":[294],"exposure":[301],"12":[304],"months.":[305],"Data":[306],"indicate":[307],"appropriate":[308],"modulation":[309],"NF-\u03baB,":[312],"suggest":[317],"clinical":[318],"benefit":[319],"associated":[320],"this":[322],"novel":[323],"mechanism,":[324],"including":[325],"PR":[327],"disease":[330],"stabilization":[331],"patients.":[334],"Phase":[335],"trials":[337],"have":[338],"begun.":[339],"Author":[340],"Disclosure":[341],"Employment":[342],"Leadership":[344],"Consultant":[345],"Advisory":[347],"Role":[348],"Stock":[349],"Ownership":[350],"Honoraria":[351],"Research":[352],"Expert":[353],"Testimony":[354],"Other":[355],"Remuneration":[356],"Reata":[357,360,363],"Pharmaceuticals,":[358,361,364],"Inc":[359,362,365]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}